Introduction {#sec1}
============

Aortic stenosis (AS) is the most common valvular heart disease in adults in Europe and North America. Its prevalence in the community increases with age \[[@cit0001]\], currently at about 5% (severe AS) in the population aged 75 and over \[[@cit0002]\].

Management of patients with AS depends on accurate diagnosis of the cause and stage of the disease process \[[@cit0003]\]. The first and definitive therapeutic choice for a growing number of elderly patients with symptomatic AS is surgical treatment (surgical aortic valve replacement -- SAVR), performed either conventionally or mini-invasively, using different types of valves, mainly biological (including stentless and sutureless).

This method however is associated with elevated risk in approximately 1/3 of patients with severe symptomatic AS (40%) \[[@cit0004]\]. Although operative mortality of SAVR is low in a selective group of elderly patients, it increases with number and severity of co-morbidities \[[@cit0005]\]. Transcatheter aortic valve implantation (TAVI) constitutes a safe and effective therapeutic alternative for this population. As an innovative, costly method of treatment, it requires however careful monitoring of its course, documenting its early and long-term results, assessment of its safety and medical-economic cost-effectiveness. A medical registry seems to be an excellent tool to perform such analysis.

TAVI Program in Poland {#sec1.1}
----------------------

The transcatheter aortic valve procedure was introduced in Poland in 2008, initially in two centers: the John Paul II Hospital in Krakow and the Silesian Center for Heart Diseases in Zabrze. The first Polish TAVI from the transapical approach was performed in Krakow, and the first from the transfemoral approach in Zabrze. The first patients were three elderly women (a 77-year old who underwent the procedure in Krakow and a 77- and 76-year old in Zabrze) with severe symptomatic AS, non-eligible for SAVR due to co-morbidities ([Fig. 1](#f0001){ref-type="fig"}). Within a short period of time, from November 25 to March 30, 2009, 19 TAVI procedures were performed, in four Polish centers (aforementioned Silesian Center for Heart Diseases in Zabrze, John Paul II Hospital in Krakow, Institute of Cardiology in Warsaw and Upper Silesian Medical Center in Katowice). Results of those first implantations were presented in the POL-TAVI First Report \[[@cit0006]\].

![First TAVI patients with Zabrze TAVI team and Matthias Thielmann (Essen, Germany) as proctor, Zabrze, November 26^th^, 2008. Source: SCCS archives](KITP-13-28999-g001){#f0001}

Success of the first percutaneous aortic valve implantations resulted in launching the TAVI program in other centers across Poland authorized by the Ministry of Health, and later the National Health Fund. In 2012 there were 11 active TAVI centers, and in 2013 there were 18. Since 2014 the TAVI program has been conducted in 21 hospitals and the number of procedures has systematically increased ([Fig. 2](#f0002){ref-type="fig"}).

![Development of TAVI in Poland in years 2013--2015 -- data from POL-TAVI Registry](KITP-13-28999-g002){#f0002}

TAVI application vs. recommendation {#sec1.2}
-----------------------------------

Initially TAVI was recommended for end-stage patients with severe symptomatic AS \[[@cit0007]\]. With increased clinical application, and further device market development, TAVI has become a common therapeutic option for high-risk patients, unsuitable for surgery. In some countries, however, increased experience and good clinical short- and medium-term results have led to an undesired increase in TAVI application, performed, regardless of recommendations, also in intermediate-risk patients (e.g. porcelain aorta) \[[@cit0008]\]. Studies confirm that the observed shift in number of TAVI procedures often results also from inappropriate qualification criteria on the basis of which patients are being referred for TAVI (e.g. advanced age solely) \[[@cit0009]\].

The large Euro Heart Survey on Valvular Heart Disease and other trials confirmed the existing gap between guidelines and real application of TAVI in clinical practice \[[@cit0004]\].

These observations resulted in development of the updated ESC/EACTS Guidelines on Vascular Heart Disease Management (2012), where indications and contraindications to TAVI were clearly defined.

The results of those studies revealed and stressed also urgent need for development of registries -- a tool allowing collecting and monitoring the adherence to the guidelines, frequency of TAVI application, analysis of treatment course, and evaluation of efficacy of early and long-term outcomes.

Aim {#sec2}
===

The aim of this paper is to present the design and rationale for creation of the first National Cardiac-Cardiac Surgical Registry of Percutaneous Aortic Valve Treatment POL-TAVI, to describe its genesis and to highlight its key assumptions, aims and potential benefits for patients, medical professionals, and the payer.

Material and methods {#sec3}
====================

Genesis and development of POL-TAVI Registry {#sec3.1}
--------------------------------------------

The aforementioned POL-TAVI First Report was the first medical-economic analysis of transcatheter aortic valve implantation in Poland. The aim of this report was to monitor and evaluate treatment outcomes, safety, quality and cost-effectiveness of this innovative, costly method of treatment in Poland.

By 2011, almost every Polish center authorized by the Ministry of Health to perform TAVI conducted its own internal TAVI registry, designed according to its own project and its own clinical-scientific and organizational needs. Such a solution had enabled heart teams to monitor and assess their treatment outcomes; lack of unification and standardization, however, made comparison of treatment results with other Polish and foreign centers difficult and often unreliable.

When in 2010 on the initiative of the European Society of Cardiology, within the EurObservational Research Program, the Transcatheter Valve Treatment Registry (TCVT) was created, Poland was one of 12 countries that applied for enrolment. Within 2011--2012, the TCVT Pilot Registry, conducted under the leadership of Carlo di Mario, collected data on 4571 TAVI patients across Europe \[[@cit0010]\].

The participation of Poland (back then of all 11 Polish TAVI centers) in the TCVT Pilot Registry, converted later into a long-term registry, allowed for the first time for unification of the TAVI dataset, and credible assessment of national TAVI outcomes on the broader scale, including in comparison with other European centers.

Experience gained from the TCVT-Pilot Registry, but also from successful coordination of national, large, long-term registries, such as AMI-PL (National Database of Myocardial Infarction) and KROK (National Registry of Cardiac Surgery), resulted in development of the Polish TAVI registry. In 2013, on the initiative of Marian Zembala, national TAVI coordinator and long-term national consultant in cardiac surgery, as well as Waldemar Banasiak, president of the Polish Cardiac Society at the time, the first nation-wide Cardiac-Cardiac Surgical Registry of Transcatheter Aortic Valve Implantation -- POL-TAVI -- was launched. The initiative was strongly supported by the European Society of Cardiology, TCVT Registry leaders and the previous and present Board of the Polish Cardiac Society.

To ensure high quality, reliability and proper management of the Registry, the Steering Committee, composed of representatives of the leading Polish TAVI centers, cardiology and cardiac surgery domains, was constituted. It has been governed by Marian Zembala (chairman), Janina Stępińska (vice chairman), Grzegorz Opolski (vice chairman), Adam Witkowski (secretary) and members: Waldemar Banasiak, Dariusz Dudek, Krzysztof Filipiak, Piotr Hoffman, Zbigniew Kalarus, Bogusław Kapelak, Tomasz Kukulski, Bohdan Maruszewski, Andrzej Ochała, Piotr Olszówka, Jan Rogowski, Piotr Szymański and Krzysztof Wilczek. In addition, a POL-TAVI working group -- an auditing team, including authors of this paper -- was set up to monitor the completeness and quality of data reported.

Rationale and purposes of POL-TAVI Registry {#sec3.2}
-------------------------------------------

Development of the POL-TAVI Registry was based on the following key assumptions:

-   reporting to the registry will be obligatory for all TAVI hospitals and constitutes one of the conditions of contract for TAVI between a given center and a payer;

-   registry will enable collection of all TAVI data in one place, in one standardized pattern;

-   POL-TAVI will serve both clinicians and the payer as a national benchmark of treatment outcomes;

-   credibility and completeness of data will be verified through internal and external regular audits. Moreover, systematic national audits of mortality reports will be performed;

-   the Registry will serve as a national database for scientific purposes (material for publications, reports, presentations at national and international meetings), enabling dissemination of Polish results and promotion of the Polish TAVI program worldwide.

Furthermore, key messages -- tasks of the POL-TAVI Registry -- were set up: the main aim of the Registry is to assess and develop optimal management of severe symptomatic AS, a condition which has and will have, due to the aging population, a significant impact on society, and on the medical, economic and social burden of valvular heart disease in Poland.

The specific aims of the registry can be summarized as follows:

-   to monitor TAVI indications and procedural strategy (access site, device distribution, type of anaesthesia);

-   to supervise adherence to the guidelines and compliance with indications/contraindications to TAVI (exclude excessive application of costly devices, exclude inappropriate application of TAVI in patients too sick to benefit in terms of mortality and quality of life) (following TCVT Registry assumptions and indications);

-   to assess objectively and non-commercially peri-procedural device success;

-   to monitor and improve safety, quality and efficacy of treatment;

-   to assess early- and long-term results of this novel method of treatment in order to develop the most optimal therapeutic follow-up strategy;

-   to monitor and evaluate cost-effectiveness of TAVI in Poland;

-   to ensure the decision for TAVI is made by a multi-disciplinary heart team (in accordance with guidelines) to guarantee the optimal treatment of patients with severe symptomatic AS;

-   based on the results of POL-TAVI, to continue development and improvement of this therapeutic method in Poland.

Results {#sec4}
=======

POL-TAVI Registry: design, dataset {#sec4.1}
----------------------------------

First POL-TAVI CRF, created by the authors, was largely based on well-proven European TCVT Registry forms (approval of TCVT Registry leaders was obtained). The electronic database was developed by MAGNUM 2, a company with extensive documented experience in development and coordination of medical databases. Additional documents, such as a written patient consent form, downloadable CRF, and POL-TAVI user's manual were prepared. All materials are published at POL-TAVI homepage and are easily accessible for Registry users.

The web-based POL-TAVI registry consists of three main parts, divided into 8 medical cards, collecting data on patient's history, in-hospital and follow-up period:

I.  Baseline characteristics Interview (Wywiad) ([Fig. 3](#f0003){ref-type="fig"})

II. Procedural data 2.Assessment (Ocena) ([Fig. 4](#f0004){ref-type="fig"})3.Medical examinations (Badania) ([Figs. 5](#f0005){ref-type="fig"}, [6](#f0006){ref-type="fig"})4.Procedure (Zabieg) ([Figs. 7](#f0007){ref-type="fig"}, [8](#f0008){ref-type="fig"})5.Discharge (Wypis) ([Fig. 9](#f0009){ref-type="fig"})

III. Follow-up 6.1 month (Kontrola 1 m-c) ([Figs. 10](#f0010){ref-type="fig"}, [11](#f0011){ref-type="fig"})7.6 months (Kontrola 6 m-cy)8.12 months (Kontrola 12 m-cy)

In 2016, the authors of this paper performed reconstruction of the Registry, updating it to the current needs and requirements, extending so far questionnaire -- among others -- for novel devices, adopting it to the current standardized endpoint definitions for TAVI -- The Valve Academic Research Consortium-2 (VARC-2) \[[@cit0011]\]. Aside from ESC/EACTS 2014 Guidelines, important evaluation criteria from AHA/ACC 2014 Guidelines were implemented (e.g. frailty scale, STS score) ([Fig. 12](#f0012){ref-type="fig"}).

![Interview -- patient profile: medical history, risk factors](KITP-13-28999-g003){#f0003}

![TAVI Heart Team assessment: indications and contraindications to TAVI](KITP-13-28999-g004){#f0004}

![Pre-procedural examination](KITP-13-28999-g005){#f0005}

![Pre-procedural imaging](KITP-13-28999-g006){#f0006}

![Documentation of TAVI procedure](KITP-13-28999-g007){#f0007}

![Immediate TAVI results. Periprocedural complications](KITP-13-28999-g008){#f0008}

![Discharge](KITP-13-28999-g009){#f0009}

![Follow-up after 1 month -- history of potential re-hospitalizations](KITP-13-28999-g010){#f0010}

![Follow-up after 1 month: TAVI investigations, quality of life assessment](KITP-13-28999-g011){#f0011}

![Inclusion of STS Risk Calculator and Clinical Frailty Scale in updated POL-TAVI CRF -- adaptation to 2014 AHA/ACC Guideline for the Management of Patients with VHD](KITP-13-28999-g012){#f0012}

The range of the survey was also extended for the transcatheter mitral valve replacement part, transforming the aortic registry into the first nation-wide database of transcatheter valve treatment in the country.

In total POL-TAVI collects over 370 parameters per patient in the baseline and procedural part together and nearly 100 (almost 300 in total) per patient in the follow-up card. A detailed list is available at [www.poltavi.pl](http://www.poltavi.pl)

The Registry, in its new edition, will be launched in January 2017.

Data security {#sec4.2}
-------------

Access to the POL-TAVI Registry is given only to authorized representatives of TAVI centers, upon receipt of written authorization by the POL-TAVI management team. Registered users log into their center's individual account. All data are secured in accordance with the national big data security regulations.

Publications from POL-TAVI REGISTRY. e-Library {#sec4.3}
----------------------------------------------

The extensive material collected in the POL-TAVI Registry since January 1, 2013 (until December 31, 2015 including data on 1466 TAVI patients, 1471 TAVI procedures) constitutes a valuable source for multidimensional analysis and scientific research.

Use of POL-TAVI for scientific purposes (publications, presentation at national and international conferences, other) has been precisely defined in POL-TAVI regulations (available at [www.poltavi.pl](http://www.poltavi.pl)) and supervised by the Steering Committee.

Up to 2016 the following papers, based on POL-TAVI national results, were published or accepted for publication in peer-reviewed, international medical journals:

-   Mitral and aortic regurgitation following transcatheter aortic valve replacement -- Szymański *et al.* \[[@cit0012]\];

-   Paravalvular leak after transcatheter aortic valve implantation (TAVI): short-term results. Data from Polish national POL-TAVI registry -- Kleczyński *et al.* \[[@cit0013]\];

-   Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from Polish Registry POL-TAVI -- Czerwińska-Jelonkiewicz *et al.* \[[@cit0014]\];

-   Improvement of quality of life following transcatheter aortic valve implantation in elderly -- multi-center study based on Polish National TAVI Registry -- Stańska *et al.* \[[@cit0015]\]

Further manuscripts, documenting Polish TAVI results, are awaiting acceptance for publishing.

To provide researchers with easy access to literature on transcatheter valve treatment in Poland, on the initiative of Marian Zembala, chairman of the POL-TAVI Registry, in 2016 the first TAVI e-library, including all papers published so far on TAVI in Poland, was created. It is available at the POL-TAVI homepage (open access -- registration not required).

Conclusions {#sec5}
===========

Transcatheter aortic valve implantation has been developed as an answer for clinical needs and expectations of patients disqualified by the TAVI team from conventional surgery. It constitutes a safe and effective therapeutic alternative for symptomatic AS patients with documented high risk. Performed both by cardiologists and cardiac surgeons as operators, working together as the TAVI team, this method, however, as a still new, challenging and costly option, requires careful and reliable multidimensional analysis.

The creation of the National Polish Cardiac-Cardiac Surgical Registry of Transcatheter Aortic Valve Implantation POL-TAVI has allowed for the first time for systematic collection and monitoring of Polish TAVI data, and evaluation of access of Polish patients to this method of treatment.

The Registry has enabled the assessment of quality of early and long-term results of treatment (using different devices), in patients with symptomatic AS and documented high risk or non-eligible for surgery due to severe co-morbidities or other contraindications (e.g. porcelain aorta).

Moreover, POL-TAVI has permitted reliable and thorough early, middle- and late-term assessment of TAVI safety, which matters especially in view of the more and more often observed premature calcification and damage of the implanted TAVI biological valve within 5 years after the procedure.

Finally, the POL-TAVI Registry has enabled, for the first time on such a scale, a systematic medical-economic-organizational analysis of the efficacy and profitability of this new alternative method of treatment -- a method which should be dedicated exclusively to elderly high-risk patients. It needs to be highlighted that TAVI, without medical justification, should not replace the still fundamental, considered as safe and effective, surgical aortic valve implantation -- evidence of which may be the data of the National Registry of Cardiac Surgery KROK and current SAVR outcomes: in 2015 in Poland 3505 patients underwent surgical aortic valve implantation (564 mini-invasively), with average in-hospital mortality of 3.7% (2.4% respectively).

Having in mind the limited supplies and budget of the payer, and the level of health services reimbursement, careful and reasonable monitoring and systematic assessment of TAVI vs. SAVR application based on the objective early- and long-term data from the registry are essential.

In sum, the POL-TAVI Registry constitutes an important and valuable tool for patients, medical professionals and the payer.
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